A multicenter retrospective study comparing the safety and efficacy of carbon ion radiotherapy and radiofrequency ablation in early stage hepatocellular carcinoma

A multicenter retrospective study comparing the safety and efficacy of carbon ion radiotherapy and radiofrequency ablation in early stage hepatocellular carcinoma - A multicenter retrospective study comparing the safety and efficacy of carbon ion radiotherapy and radiofrequency ablation in early stage hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047923

Enrollment

450

Registered

2022-06-03

Start date

2019-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with first hepatocellular carcinoma between April 2003 and March 2018 and treated with carbon ion radiotherapy or radiofrequency ablation. Hepatocellular carcinoma within 5 cm for a single tumor or within 3 cm for 2 or 3 tumors.

Exclusion criteria

Exclusion criteria: Patients with evidence of vascular invasion or distant metastasis. Patients with advanced carcinoma at the time of initial diagnosis of hepatocellular carcinoma. Patients with Child-Pugh C at the time of diagnosis of initial hepatocellular carcinoma. Patients who refuse to participate in this study.

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Progression free survival Local control Complications ALBI score after six months of treatment	—

Countries

Japan

Contacts

Public ContactNaoto Fujita

Chiba university Department of Gastroenterology

n.fujita53@gmail.com043-222-7171

Outcome results